These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
79 related items for PubMed ID: 18804493
21. Biological activity of AC3174, a peptide analog of exendin-4. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM. Regul Pept; 2007 Jun 07; 141(1-3):113-9. PubMed ID: 17292977 [Abstract] [Full Text] [Related]
22. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T. Breast Cancer Res Treat; 2012 Apr 07; 132(2):449-61. PubMed ID: 21638053 [Abstract] [Full Text] [Related]
23. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. J Control Release; 2010 May 21; 144(1):10-6. PubMed ID: 20093159 [Abstract] [Full Text] [Related]
24. Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Zhang Y, Zhang J, Wang Q, Lei X, Chu Q, Xu GT, Ye W. Invest Ophthalmol Vis Sci; 2011 Jan 05; 52(1):278-85. PubMed ID: 20688733 [Abstract] [Full Text] [Related]
25. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Glaser S, Benedetti A. Gastroenterology; 2007 Jul 05; 133(1):244-55. PubMed ID: 17631146 [Abstract] [Full Text] [Related]
26. Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective Akt phosphorylation in target tissues of adult male rat. Muthusamy T, Murugesan P, Balasubramanian K. Metabolism; 2009 Nov 05; 58(11):1581-92. PubMed ID: 19615701 [Abstract] [Full Text] [Related]
28. GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients. González N, Sancho V, Martín-Duce A, Tornero-Esteban P, Valverde I, Malaisse WJ, Villanueva-Peñacarrillo ML. Int J Mol Med; 2005 Oct 05; 16(4):747-52. PubMed ID: 16142415 [Abstract] [Full Text] [Related]
29. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats. Chan P, Liu IM, Tzeng TF, Yang TL, Cheng JT. Diabetes Obes Metab; 2007 Jan 05; 9(1):39-49. PubMed ID: 17199717 [Abstract] [Full Text] [Related]
30. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Diabetologia; 2002 Oct 05; 45(10):1410-5. PubMed ID: 12378382 [Abstract] [Full Text] [Related]
31. Participation of protein kinases in the stimulant action of GLP-1 on 2-deoxy-D-glucose uptake by normal rat skeletal muscle. Acitores A, González N, Sancho V, Arnés L, Valverde I, Malaisse WJ, Villanueva-Peñacarrillo ML. Horm Metab Res; 2005 May 05; 37(5):275-80. PubMed ID: 15971149 [Abstract] [Full Text] [Related]
32. Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. Lietzau G, Nyström T, Östenson CG, Darsalia V, Patrone C. Oncotarget; 2016 Feb 02; 7(5):5865-76. PubMed ID: 26744321 [Abstract] [Full Text] [Related]
33. Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals. Malendowicz LK, Nowak KW. Int J Mol Med; 2002 Sep 02; 10(3):327-31. PubMed ID: 12165809 [Abstract] [Full Text] [Related]
34. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Sonne DP, Engstrøm T, Treiman M. Regul Pept; 2008 Feb 07; 146(1-3):243-9. PubMed ID: 17976835 [Abstract] [Full Text] [Related]
36. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives. Son S, Chae SY, Kim CW, Choi YG, Jung SY, Lee S, Lee KC. J Med Chem; 2009 Nov 12; 52(21):6889-96. PubMed ID: 19827752 [Abstract] [Full Text] [Related]
37. Control of liver glucokinase activity: A potential new target for incretin hormones? Francini F, Massa ML, Polo MP, Villagarcía H, Castro MC, Gagliardino JJ. Peptides; 2015 Dec 12; 74():57-63. PubMed ID: 26524624 [Abstract] [Full Text] [Related]
38. Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model. Bulchandani D, Nachnani JS, Herndon B, Molteni A, Pathan MH, Quinn T, Hamdan HA, Alba LM, Graves L. Eur J Pharmacol; 2012 Sep 15; 691(1-3):292-6. PubMed ID: 22819704 [Abstract] [Full Text] [Related]
39. Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level. Yang Y, Ma D, Xu W, Chen F, Du T, Yue W, Shao S, Yuan G. Mol Cell Neurosci; 2016 Jan 15; 70():68-75. PubMed ID: 26640240 [Abstract] [Full Text] [Related]
40. Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury. Yamamoto K, Amako M, Yamamoto Y, Tsuchihara T, Nukada H, Yoshihara Y, Arino H, Fujita M, Uenoyama M, Tachibana S, Nemoto K. Biomed Res Int; 2013 Jan 15; 2013():315848. PubMed ID: 23984340 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]